One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
CEL-SCI Corporation logo
CEL-SCI Corporation CVM
$ 1.44 6.67%
report update icon

Quarterly report 2026-Q2
added 05-15-2026

CEL-SCI Corporation Balance Sheet 2025-2008 | CVM

Brief overview of CEL-SCI Corporation's assets and capital

The review uses the five latest available annual reports between 2021 and 2025.

Assets declined from $75.9 million to $28.2 million, or -62.9%. The contraction calls for context such as disposals, restructuring or weaker operations.

Liabilities expanded faster than the asset base, -36.9% versus -62.9%. Debt-service capacity deserves attention.

The equity ratio reached 56.7% from 74.5%. A high capital share reduces dependence on liabilities.

Net debt moved below zero to -$5.1 million, reflecting surplus cash over debt.

The cash reserve occupies 38.9% of the balance sheet, previously 47.5%. It is one marker of short-term resilience.

Retained earnings are negative at -$539.4 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.

Overall assessment

CEL-SCI Corporation's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.

Annual Balance Sheet CEL-SCI Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Net Debt

-5.1 M 3.45 M 6 M -10.8 M -22.8 M -14.4 M 5.06 M 3.07 M 11.8 M -2.92 M -4.47 M -7.39 M 1.09 M -2.84 M 738 K - - -

Long Term Debt

5.68 M 7.96 M 9.95 M 11.7 M 13.3 M - - - - - - - - - - - - -

Long Term Debt Current

167 K 227 K 197 K 171 K - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - 19.5 M 20.4 M 15.4 M 8.54 M 13.8 M 5.63 M 593 K 7.13 M 2.32 M - - -

Total Current Liabilities

5.13 M 4.62 M 5.59 M 4.66 M 3.94 M 4.27 M 3.02 M 9.23 M 10.8 M 4.01 M 6.71 M 3.15 M 3.55 M 1.91 M 7.22 M 3.3 M - -

Total Liabilities

12.2 M 14.1 M 17.3 M 18.4 M 19.3 M 20.8 M 22.5 M 29.6 M 26.3 M 12.6 M 20.7 M 8.79 M 4.14 M 9.04 M 9.55 M 9.95 M - -

Retained Earnings

-539 M -514 M -487 M -455 M -418 M - -354 M -332 M -300 M -286 M -274 M -240 M -212 M -203 M -188 M -162 M - -

Total Assets

28.2 M 27 M 30.5 M 50.5 M 75.9 M 40.5 M 27.6 M 29.6 M 22.9 M 11.6 M 15.4 M 19.2 M 10.8 M 16.1 M 18.6 M 37.8 M - -

Cash and Cash Equivalents

11 M 4.74 M 4.15 M 22.7 M 36.1 M 15.5 M 8.44 M 10.3 M 2.37 M 2.92 M 5.73 M 8.51 M 41.6 K 3.94 M 4.26 M 26.6 M 33.6 M 711 K

Book Value

16 M 12.9 M 13.2 M 32.2 M 56.5 M 19.7 M 5.13 M 916 -3.34 M -956 K -5.23 M 10.4 M 6.7 M 7.03 M 9.08 M 27.9 M - -

Total Shareholders Equity

16 M 12.9 M 13.2 M 32.2 M 56.5 M 19.7 M 5.13 M 916 -3.34 M -679 K -4.76 M 10.4 M 6.7 M 7.03 M 9.08 M 27.9 M 8.84 M 10.8 M

All numbers in USD currency

Quarterly Balance Sheet CEL-SCI Corporation

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

4.43 M 5.07 M 5.07 M 5.68 M 6.27 M 6.85 M 7.41 M 7.96 M 8.48 M 8.99 M 9.47 M 9.95 M 10.4 M 10.9 M 11.3 M 11.7 M 12.1 M 12.5 M 12.9 M 13.3 M 13.6 M 13.3 M 11.5 M 11.8 M 11.8 M 11.8 M 12.5 M 13.5 M 13.5 M 12.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

10.8 M 11.8 M 11.8 M 12.2 M 13.3 M 13.8 M 14.4 M 14.1 M 15.6 M 15.7 M 16.1 M 17.3 M 17.5 M 18 M 18 M 18.4 M 18.2 M 19 M 18.3 M 19.3 M 19.8 M 19.3 M 20.8 M 20.8 M 20.8 M 20.8 M 22.5 M 22.5 M 22.5 M 22.5 M 23.2 M 29.6 M 29.6 M 29.6 M 27 M 26.3 M 26.3 M 26.3 M 18.6 M 25.6 M 25.6 M 5.49 M 16.5 M 33.3 M 20.5 M 20.5 M 7.71 M 8.79 M 8.79 M 8.79 M 9.69 M 4.14 M 4.14 M 4.14 M 10.4 M 9.04 M 9.04 M 9.04 M 8.57 M 9.55 M 9.55 M 9.55 M

Retained Earnings

-550 M -545 M -545 M -539 M -533 M -528 M -521 M -514 M -508 M -501 M -494 M -487 M -479 M -471 M -463 M -455 M -446 M -437 M -427 M -418 M -410 M -418 M -390 M -382 M -382 M -382 M -357 M -354 M -354 M -359 M -330 M -332 M -332 M -332 M -306 M -300 M -300 M -300 M -282 M -285 M -285 M -282 M -272 M -274 M -274 M -274 M -247 M -239 M -240 M -240 M -216 M -212 M -212 M -212 M -205 M -203 M -203 M -203 M -191 M -188 M -188 M -188 M

Total Assets

17.7 M 22.9 M 22.9 M 28.2 M 20.3 M 21.8 M 25.7 M 27 M 24.1 M 30 M 28.7 M 30.5 M 32.3 M 38.2 M 44.6 M 50.5 M 56.9 M 64.2 M 69.7 M 75.9 M 79.6 M 75.9 M 49.6 M 40.5 M 40.5 M 40.5 M 31.5 M 27.6 M 27.6 M 29.5 M 25.9 M 29.6 M 29.6 M 29.6 M 22.2 M 22.9 M 22.9 M 22.9 M 23.3 M 24.9 M 24.9 M 9.93 M 20 M 28.6 M 15.4 M 15.4 M 19.6 M 19.2 M 19.2 M 19.2 M 24.8 M 10.8 M 10.8 M 10.8 M 22 M 16.1 M 16.1 M 16.1 M 16.7 M 18.6 M 18.6 M 18.6 M

Cash and Cash Equivalents

1.89 M 6.28 M 6.28 M 11 M 1.79 M 1.92 M 4.61 M 4.74 M 385 K 5.31 M 3.24 M 4.15 M 5.14 M 10 M 18 M 22.7 M 28.1 M 34.3 M 37.1 M 36.1 M 36 M 36.1 M 21.9 M 15.5 M 15.5 M 21.9 M 9.38 M 8.44 M 8.44 M 9.38 M 6.68 M 10.3 M 10.3 M 6.68 M 2.14 M 2.37 M 2.37 M 2.14 M 2.39 M 2.92 M 2.92 M 2.39 M 10.4 M 5.73 M 5.73 M 10.4 M 9.46 M 8.51 M 8.51 M 9.46 M 13.5 M 41.6 K 41.6 K 13.5 M 10.7 M 3.94 M 3.94 M 10.7 M 3.46 M 4.26 M 4.26 M 3.46 M

Book Value

6.87 M 11.1 M 11.1 M 16 M 7.02 M 8 M 11.3 M 12.9 M 8.47 M 14.3 M 12.7 M 13.2 M 14.8 M 20.1 M 26.6 M 32.2 M 38.7 M 45.1 M 51.4 M 56.5 M 59.8 M 56.5 M 28.8 M 19.7 M 19.7 M 19.7 M 8.95 M 5.13 M 5.13 M 6.97 M 2.71 M 916 916 916 -4.83 M -3.34 M -3.34 M -3.34 M 4.69 M -679 K -679 K 4.43 M 3.53 M -4.76 M -5.09 M -5.09 M 11.8 M 10.4 M 10.4 M 10.4 M 15.1 M 6.7 M 6.7 M 6.7 M 11.6 M 7.03 M 7.03 M 7.03 M 8.11 M 9.08 M 9.08 M 9.08 M

Total Shareholders Equity

6.87 M 11.1 M 11.1 M 16 M 7.02 M 8 M 11.3 M 12.9 M 8.47 M 14.3 M 12.7 M 13.2 M 14.8 M 20.1 M 26.6 M 32.2 M 38.7 M 45.1 M 51.4 M 56.5 M 59.8 M 29.3 M 28.8 M 28.8 M 28.8 M 28.8 M 8.95 M 8.95 M 8.95 M 8.95 M 2.71 M 2.71 M 2.71 M 2.71 M -4.83 M -3.34 M -3.34 M -4.83 M 4.69 M -679 K -679 K 4.43 M 3.53 M -4.76 M -5.09 M -5.09 M 11.8 M 10.8 M 10.4 M 10.4 M 15.1 M 6.7 M 6.7 M 6.7 M 11.6 M 7.03 M 7.03 M 7.03 M 8.11 M 9.08 M 9.08 M 9.08 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of CEL-SCI Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
Sesen Bio Sesen Bio
SESN
- 7.29 % $ 127 M usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
MEI Pharma MEI Pharma
MEIP
- 10.43 % $ 20.5 M usaUSA
Palatin Technologies Palatin Technologies
PTN
- - $ 13 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 4.21 4.99 % $ 653 M usaUSA
AbbVie AbbVie
ABBV
$ 291.22 1.06 % $ 515 B usaUSA
22nd Century Group 22nd Century Group
XXII
$ 1.56 -19.17 % $ 287 K usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 313.68 -18.01 % $ 24.5 B usaUSA
Biogen Biogen
BIIB
$ 248.51 1.88 % $ 36.4 B usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 1.73 -2.15 % $ 4.26 B israelIsrael
Theratechnologies Theratechnologies
THTX
- - $ 83.9 M canadaCanada
Exelixis Exelixis
EXEL
$ 69.55 1.22 % $ 18.9 B usaUSA
Geron Corporation Geron Corporation
GERN
$ 0.99 3.97 % $ 660 M usaUSA
Gilead Sciences Gilead Sciences
GILD
$ 166.9 -0.4 % $ 208 B usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 8.46 -0.12 % $ 5.75 B spainSpain
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 155.97 -0.44 % $ 20.4 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.31 -3.69 % $ 88.1 M germanyGermany
INmune Bio INmune Bio
INMB
$ 1.12 -4.68 % $ 27.7 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
$ 114.55 5.32 % $ 22.8 B usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
$ 274.89 0.95 % $ 662 B usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
- -3.76 % $ 3.47 M usaUSA
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 1.02 3.75 % $ 235 M usaUSA
BioVie BioVie
BIVI
$ 1.33 9.92 % $ 1.96 M usaUSA
Longeveron Longeveron
LGVN
$ 1.82 6.43 % $ 32 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
- - $ 58.1 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Mustang Bio Mustang Bio
MBIO
$ 0.39 0.15 % $ 1.91 M usaUSA
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
- -60.05 % $ 125 K usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 1.63 1.87 % $ 2.68 M israelIsrael
Mesoblast Limited Mesoblast Limited
MESO
$ 14.26 1.13 % $ 17.2 B australiaAustralia
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 93.81 0.28 % $ 4.71 B usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Codexis Codexis
CDXS
$ 1.09 6.37 % $ 95 M usaUSA